CHINA REGENERATIVE MEDICINE INTERNATIONAL LIMITED Hong Kong, 4 September 2017- China Regenerative Medicine International Limited ("China Regenerative Medicine" or "the Company", stock code: 8158.HK, together with its subsidiaries, collectively "the Group") is pleased to announced that on August 28, Mr. Chen Chunguo, CEO of China Regenerative Medicine and Mr. Min Zhidong, Chairman of Zhonghua Financial Holdings Limited led the delegation on visit to Shaanxi Xixian New Area, and were received by Mr. Yue Huafeng, director of the Xixian New Area administrative committee. Both parties had an in-depth discussion on the enhanced strategic deployment of the regenerative medicine industry and the development of hi-tech medical cosmetics industrial park.
Mr. Chen Chunguo, CEO of China Regenerative Medicine International Limited, the first Chinese professional hi-tech enterprise on R&D, production and sales of the tissue engineering and regenerative medical products, gave an introduction on the group's tissue engineering and cell preparation, manufacturing and sales, the strategic deployment of aspects including the cosmetics and hospital management, as well as the strategic development direction in Hong Kong, mainland China, America, Europe, Africa and Far East Areas. The Company looks forward to further cooperating with Xixian New Area, and jointly promoting the development of regenerative medical industrial park.
23/F., Sunshine Plaza, 353 Lockhart Road, Wanchai, Hong Kong
香港灣仔駱克道 353 號三湘大廈 23 樓 Tel: 852 2363 9292 Fax: 852 2363 1272
Mr. Yue Huafeng said, "As the first state-level new area approved by the State Council, Xi Xian New Area, with a theme of innovative city development direction, enjoys an outstanding geographical advantage and rich historical resources. Currently, the basic urban infrastructure has already been in place, laying a solid foundation for accelerating the cultivation of modern innovation industry. China Regenerative Medicine, the pioneer of biomedical frontier in China, has broad prospects for cooperation regarding the development of innovation industry within the New Area." He looks forward to enhancing cooperation between both parties in the coming future by introducing the advanced technologies from the Company and strengthening both products' R&D and brand marketing. In addition, Mr. Yue welcomed the Company to help build the New Area as an "Industrial Base for Chinese Cosmeceuticals" and Zhonghua Financial Holdings to establish industry fund and M&A fund with the government investment companies in the New Area, in order to give priority support for investment by new industries and M&A projects of overseas new technologies in such area. The Shaanxi provincial government dedicated to Xixian New Area will provide full support including human resources and financial resources with relevant policy, with an aim to achieve win- win cooperation in its industrialization.
The Xixian New Area covers all the seven counties and 23 villages, towns and sub-districts of the two cities of Xi'an and Xianyang, Shaanxi province, a total of 882 square kilometers. A core region of the Guanzhong - Tianshui Economic Zone, Xixian has multiple advantages for fast development, including a favorable location and economy, abundant education resources and S&T talented personnel, significant historical and cultural heritage, and a great natural environment. It is influential in the strategy of western development, integration of Xi'an and Xianyang, development of northwest China, construction of Silk Road economic belt and China's opening to the West. Also, it has a leading role in exemplifying a new urbanization with Chinese characteristics and improving the mechanisms of urban and rural integrated development.
-End-
About China Regenerative Medicine International Limited23/F., Sunshine Plaza, 353 Lockhart Road, Wanchai, Hong Kong
香港灣仔駱克道 353 號三湘大廈 23 樓 Tel: 852 2363 9292 Fax: 852 2363 1272
China Regenerative Medicine International Limited，listed on the GEM Board of The Stock Exchange, stock code :8158. China Regenerative Medicine is a high-end new technology enterprise, principally engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The Group has accomplished the research and development and commercialization platform of tissue engineering and applied for more than 140 domestic and overseas patents on three major business segments, namely tissue engineering, cell therapy and cosmetics, including "ActivSkin", the only tissue-engineered skin developed in China, and "Acornea", the world's first bio-engineered cornea which completed its clinical trials. For more details, please visit www.crmi.hk.
Kate Chan | May Cheng |
Senior Account Manger | Account Executive |
Tel: (852) 2363 9292 / 9345 5300 Email: katechan@chatwinpr.com | Tel: (852) 2363 9292 / 6557 2627 Email: maycheng@chatwinpr.com |
For media enquiries, please contact: Chatwin Financial PR Company Limited
23/F., Sunshine Plaza, 353 Lockhart Road, Wanchai, Hong Kong
香港灣仔駱克道 353 號三湘大廈 23 樓 Tel: 852 2363 9292 Fax: 852 2363 1272
CRMI - China Regenerative Medicine International Limited published this content on 04 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 06 September 2017 09:47:02 UTC.
Original documenthttp://www.crmi.hk/attachment/201709061741091720715861_en.pdf
Public permalinkhttp://www.publicnow.com/view/747921BDDB9E5800CE2F8BD1F76D840F92E6F74B
